Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
NCT00801151 · Institut Claudius Regaud · PHASE1 · terminated · last registry update 2026-09-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Institut Claudius Regaud |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HDAC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-30Results posted on the registry: Emory University, Standard Temozolomide + Belinostat (NCT02137759)
- 2026-10-22Also stopped (suspended): Children's Hospital Medical Center, Cincinnati, Sodium Thiosulfate (NCT05756660)
- 2026-09-30Results posted on the registry: M.D. Anderson Cancer Center, Pembrolizumab + Romidepsin (NCT03278782)
- 2026-09-22Also stopped (suspended): University of North Carolina, Chapel Hill, MGD020 + MGD014 (NCT07217379)
- 2026-09-16Results posted on the registry: Jennifer Amengual, Pralatrexate + Romidepsin (NCT01947140)
- 2026-09-16Also stopped (terminated): Jennifer Amengual, Pralatrexate + Romidepsin (NCT01947140)
- 2026-09-04Results posted on the registry: University of Utah, Ribociclib + Belinostat (NCT04315233)
- 2026-09-04Also stopped (terminated): University of Utah, Ribociclib + Belinostat (NCT04315233)
- 2026-06-18Results posted on the registry: Italfarmaco, ITF2357 (NCT06736223)
- 2026-05-18Also stopped (withdrawn): Virogen Biotechnology Inc., A-dmDT390-bisFv(UCHT1) + Vorinostat (NCT02943642)
- 2026-05-06Results posted on the registry: University of Michigan Rogel Cancer Center, Romidepsin + Ixazomib (NCT03547700)
- 2026-05-06Also stopped (terminated): University of Michigan Rogel Cancer Center, Romidepsin + Ixazomib (NCT03547700)
- 2026-03-10Results posted on the registry: University of Miami, Belinostat + Zidovudine (NCT02737046)
- 2026-03-03Results posted on the registry: National Cancer Institute (NCI), Belinostat + Pevonedistat (NCT03772925)
- 2026-03-03Also stopped (terminated): National Cancer Institute (NCI), Belinostat + Pevonedistat (NCT03772925)
- 2026-03-02Results posted on the registry: Antonio Fojo, Entinostat (NCT03211988)
- 2026-03-02Also stopped (terminated): Antonio Fojo, Entinostat (NCT03211988)
- 2026-01-30Also stopped (terminated): National Cancer Institute (NCI), Adavosertib + Belinostat (NCT02381548)
- 2025-11-10Results posted on the registry: Hoffmann-La Roche, Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody + Bevacizumab (NCT03280563)
- 2025-10-16Results posted on the registry: Therapeutic Advances in Childhood Leukemia Consortium, Decitabine + Vorinostat (NCT03263936)
- 2025-10-07Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Pembrolizumab + Entinostat (NCT03978624)
- 2025-10-06Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Pembrolizumab + Vorinostat (NCT03426891)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision